An annual gathering of industry and government officials focused on biomedical countermeasures and pandemic response has been canceled. The two-day event hosted by the Biomedical
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple oncology therapies. The British pharma will license ALT
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And another late-stage startup is
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Infectious disease professionals, bracing for an overhaul of the CDC’s vaccine advisory group, are in discussions to stand up a parallel committee of experts outside